Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.

[1]  E. Thiel,et al.  Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[2]  K. Sullivan,et al.  Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  A. Chuansumrit,et al.  Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients , 2007, American journal of hematology.

[4]  M. Gladwin,et al.  Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis , 2007, British journal of haematology.

[5]  A. Fischer,et al.  Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. , 2007, Blood.

[6]  M. Walters.  Cord blood transplantation for sickle cell anemia: Bust or boom? , 2007, Pediatric transplantation.

[7]  J. Klein,et al.  Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research , 2007, British journal of haematology.

[8]  C. Garone,et al.  No Kinetic Interaction Between Levetiracetam and Cyclosporine: A Case Report , 2007, Journal of child neurology.

[9]  L. Krishnamurti.  Hematopoietic cell transplantation for sickle cell disease: state of the art , 2007, Expert opinion on biological therapy.

[10]  J. Kurtzberg,et al.  Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. , 2006, Journal of pediatric hematology/oncology.

[11]  R. Krance,et al.  Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) , 2005, Bone Marrow Transplantation.

[12]  J. Kutok,et al.  Evidence for ineffective erythropoiesis in severe sickle cell disease. , 2005, Blood.

[13]  Cage S. Johnson,et al.  Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.

[14]  D. Bloch,et al.  Protective conditioning for acute graft-versus-host disease. , 2005, The New England journal of medicine.

[15]  Allen R. Chen,et al.  Bone marrow transplantation for sickle cell anemia: Progress and prospects , 2005, Pediatric blood & cancer.

[16]  R. Storb,et al.  Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.

[17]  R. Storb,et al.  Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning , 2005, Bone Marrow Transplantation.

[18]  J. Dipersio,et al.  A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders , 2005, Bone Marrow Transplantation.

[19]  J. Liesveld,et al.  Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin , 2005, Bone Marrow Transplantation.

[20]  M. Walters.  Stem cell therapy for sickle cell disease: transplantation and gene therapy. , 2005, Hematology. American Society of Hematology. Education Program.

[21]  S. Pakakasama,et al.  Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 lucarelli severe thalassemia patient , 2004, Bone Marrow Transplantation.

[22]  A. Svejgaard,et al.  Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  E. Manci,et al.  Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. , 2003, Blood.

[24]  P. Thall,et al.  Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  J. Kutok,et al.  Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. , 2003, Experimental hematology.

[26]  Allen R. Chen,et al.  Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[28]  S. Strober,et al.  Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  R. Storb,et al.  Hematopoietic cell transplantation for benign hematological disorders and solid tumors. , 2003, Hematology. American Society of Hematology. Education Program.

[30]  M. Steinberg.  Hydroxyurea Treatment for Sickle Cell Disease , 2002, TheScientificWorldJournal.

[31]  G. Ledderose,et al.  Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. , 2002, Experimental hematology.

[32]  K. Sullivan,et al.  Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  J. Wagner,et al.  Bone marrow transplantation without myeloablation for sickle cell disease. , 2001, The New England journal of medicine.

[34]  J. Sosman,et al.  Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease , 2000, Bone Marrow Transplantation.

[35]  C. Pegelow,et al.  Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. , 2000, Blood.

[36]  E. Vichinsky,et al.  Major changes in sickle cell disease. , 2000, Advances in pediatrics.

[37]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[38]  J. Scott,et al.  Bone marrow transplantation for sickle cell disease. , 1996, The New England journal of medicine.

[39]  J. Scott,et al.  Barriers to bone marrow transplantation for sickle cell anemia. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  M. Andreani,et al.  Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. , 1996, Blood.

[41]  H. Deeg,et al.  Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. , 1996, Blood.

[42]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[43]  M. Abboud,et al.  Bone marrow transplantation for sickle cell anemia. , 1994, The American journal of pediatric hematology/oncology.

[44]  G. Lucarelli,et al.  Bone marrow transplantation in sickle-cell anemia in Pesaro. , 1993, Bone marrow transplantation.

[45]  E. Sariban,et al.  Bone marrow transplantation for severe sickle cell anaemia , 1992, British journal of haematology.

[46]  D. Engelhard,et al.  The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders. , 1989, Transplantation proceedings.